Company Progress - The core drug CBP-307, aimed at treating autoimmune diseases such as multiple sclerosis and inflammatory bowel disease, has completed Phase I clinical trials and is set to enter Phase II trials, marking a significant advancement in the company's research pipeline [1] Funding Movements - The company completed a $25 million Series A financing round in early February 2026, led by Qiming Venture Partners, with participation from other institutions like Northern Light Venture Capital. The funds are expected to accelerate the development of innovative drug pipelines, including CBP-307 and CBP-174 [2] Institutional Perspectives - Despite significant stock price volatility, with a fluctuation range of 23.61% from February 5 to 11, institutional ratings maintain a strong buy recommendation, with multiple institutions focusing on the long-term potential of the T cell modulation platform [3]
康乃德生物研发获进展，融资支持加速药物开发
Xin Lang Cai Jing·2026-02-14 23:02